Premium
Anti‐drug monoclonal antibodies antagonize toxic effect more than anti‐tumor activity of doxorubicin
Author(s) -
Balsari A.,
Ménard S.,
Colnaghi M. I.,
Ghione M.
Publication year - 1991
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910470617
Subject(s) - monoclonal antibody , doxorubicin , in vivo , drug , pharmacology , cytotoxic t cell , epitope , in vitro , mechanism of action , antibody , drug action , monoclonal , chemistry , medicine , immunology , biology , chemotherapy , biochemistry , microbiology and biotechnology
Monoclonal antibodies (MAbs) able to bind epitope(s) of drug molecule can interfere with the biologic action of the drug. This is known and already exploited in some instances of practical relevance, as in the reversal of the digoxin effect. Similar antidotal action is exhibited by MAbs reacting with a cytotoxic antibiotic, doxorubicin (DXR), and in such a way as to induce differential neutralization of drug action. Indeed, within certain limits, the cytotoxic action of DXR in vitro as well as in vivo is more effectively neutralized on normal than on tumor cells, with consequent increase in therapeutic index.